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Abstract Recent studies show that up-regulation of cycloox-
ygenase-2 (COX-2) in human cancer cells induces activation of
matrix metalloproteinases (MMPs) and increase of metastatic
potential. In this study, we investigate the effect of a COX-2
selective inhibitor, NS398, on the expression and enzymatic
activity of MMPs in human lung cancer cells. We found that
NS398 inhibited MMP-2, not MMP-9, mRNA expression.
NS398 also reduced the amount of MMP-2, not MMP-9,
released into the medium. Additionally, this COX-2 inhibitor
attenuated the degrading activity of MMP-2 as demonstrated by
gelatin zymography. Investigation of cellular MMP-2 by
Western blotting indicated that synthesis and processing of
MMP-2 was significantly suppressed by NS398. We performed
promoter activity assay to address whether NS398 might affect
MMP-2 gene transcription. Our results indicated that NS398
directly inhibited MMP-2 promoter activity. However, the
inhibitory effect of NS398 is not fully dependent on inhibition
of COX-2 because a high concentration of NS398 was needed to
suppress MMP-2 expression and addition of prostaglandin E2
only partially reversed the action of NS398. Moreover, a non-
selective COX inhibitor indomethacin also suppressed the
expression of MMP-2. Taken together, these results indicate
that non-steroidal anti-inflammatory drugs suppress MMP-2
expression via repression of transcription and support the notion
that COX inhibitors may be useful in inhibition and/or prevention
of metastasis. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Prostaglandins (PGs) play a critical role in various physio-
logical and pathophysiological processes, including blood
clotting, kidney function, wound healing, cardiovascular dis-
ease and in£ammation [1,2]. Recent works show that cyclo-
oxygenase (COX) is the rate-limiting enzymes involved in con-
version of arachidonic acid to PGs. Two isoforms of COX,
COX-1 and COX-2, have been identi¢ed. COX-1 is expressed
constitutively in various tissues [3]. On the contrary, COX-2
expression is induced by mitogens [4,5], cytokines [6,7] or
tumor promoters [8]. Recent studies have demonstrated that
increased expression of COX-2 is frequently found in human
cancers including breast, lung, gastric, esophageal, pancreatic
and colon cancer [9^14]. In addition, lines of evidence have
indicated that non-steroidal anti-in£ammatory drugs
(NSAIDs), potent inhibitors of COXs, exert chemopreventive
e¡ect on the development of these cancers [15].
Recent studies indicated that overexpression of COX-2 may
induce tumor metastasis [16]. Interestingly, a positive correla-
tion between COX-2 expression and lymphatic invasion has
been reported in colon and gastric cancer [17,18]. However,
the function of COX-2 in tumor metastasis is unclear. The
process of tumor invasion by cancer cells involves degradation
of the underlying basement membrane, which is largely made
up of type-IV collagen. The matrix metalloproteinases
(MMPs) are a growing family of zinc-dependent endopepti-
dases that selectively degrade components of the extracellular
matrix. The MMP family can be subgrouped into at least four
types based on substrate speci¢city and sequence character-
istic. There are the interstitial collagenases, the stromelysins,
the gelatinases and the membrane-type MMPs [19]. Among
the MMPs, MMP-2 (gelatinase A) and MMP-9 (gelatinase B)
show substrate speci¢city toward type IV and V collagen and
a number of studies have demonstrated a strong correlation
between gelatinase expression and metastatic potential [20,21].
Additionally, recent works demonstrated that enforced ex-
pression of COX-2 in cells induced activation of MMP-2
and MMP-9 [22,23]. In this study, we investigate the e¡ect
of selective or non-selective COX-2 inhibitors on the expres-
sion and activation of MMPs in human lung cancer cells and
our results demonstrate that these inhibitors directly inhibit
MMP-2 expression via repression of transcription.
2. Materials and methods
2.1. Cell culture and chemicals
A549 human lung cancer cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium and F12 nutrition mixture (DMEM/F12) supple-
mented with 10% heated^inactivated fetal calf serum (FCS) and anti-
biotics. PGE2 and type-A porcine skin gelatin were obtained from
Sigma (St. Louis, MO, USA). NS398 was purchased from Biomol
(Polymouth Meeting, PA, USA). Monoclonal antibodies against hu-
man MMP-2 and MMP-9 were obtained from Oncogene Research
Product (Boston, MA, USA). Luciferase and L-galactosidase enzyme
assay systems were from Promega (Madison, WI, USA).
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2.2. RNA extraction and reverse transcriptase-polymerase chain
reaction (RT-PCR)
Total RNA was isolated from control or drug-treated cells using a
RNeasy mini kit from Qiagen (Santa Clarita, CA, USA). 1 Wg of total
RNA was reverse-transcribed to cDNA by using the OneStep RT-
PCR kit (Qiagen) according to the manufacturer’s protocol. Each
PCR reaction was performed in 50 Wl of a reaction mix, containing
10 mM Tris^HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 0.4 mM
dNTP, 600 WM primers and three units of HotStarTaq DNA poly-
merase. 5 Wl of the reverse-transcribed cDNA samples were added to
the reaction mix and ampli¢ed for 30 cycles: denaturation at 94‡C for
45 s, annealing at 60‡C for 45 s, extension at 72‡C for 2 min and ¢nal
extension at 72‡C for 10 min. A constitutively expressed gene, glyc-
eraldehyde-3-phosphate dehydrogenase (G3PDH), was used as an in-
ternal control to check the e⁄ciency of cDNA synthesis and PCR
ampli¢cation. The primer sequence and PCR product size for
MMP-2 was 5P-GTGCTGAAGGACACACTAAAGAAGA-3P and
5P-TTGCCATCCTTCTCAAAGTTGTAG-3P ; 580 bp. The primer se-
quence and PCR product size for MMP-9 was 5P-GCCACTT-
GTCGGCGATAAGG-3P and 5P-CACTGTCCACCCCTCAGAGC-
3P ; 243 bp. Ampli¢ed cDNA products were run on 2% agarose gels,
stained with ethidium bromide and visualized under UV light.
2.3. Western blot analysis
Conditioned medium was concentrated 25-fold and equal amounts,
based on cell numbers determined at the time of harvest, of super-
natant were separated by SDS^polyacrylamide gel electrophoresis
(SDS^PAGE) and Western blot analysis was performed as described
previously [24]. For analysis of cellular MMP-2 protein, cells were
treated with vehicle or NS398 (100 WM) for 24 h. Cellular proteins
were extracted and protein concentrations were determined by a BCA
assay kit. Protein level and processing of MMP-2 was investigated by
probing the nitrocellulose membranes with anti-MMP-2 monoclonal
antibody.
2.4. Zymographic assays for MMP-2
Conditioned medium was concentrated 25-fold and equal amounts,
based on cell numbers determined at the time of harvest, of super-
natant were mixed with 5Ugel loading bu¡er (0.5 M Tris^HCl, pH
6.8, 10% SDS, 50% glycerol and 0.5% bromophenol blue). Samples
were separated in a 7.5% SDS^PAGE gel containing 1 mg/ml gelatin.
The gels were washed for 1 h at room temperature in a solution
containing 2.5% (v/v) Triton X-100 and subsequently incubated with
a reaction bu¡er (50 mM Tris^HCl, pH 7.5, 150 mM NaCl, 10 mM
CaCl2 and 0.5 mM ZnCl2) at 37‡C overnight. The gels were stained
for 1 h with staining solution (0.1% Coomassie brilliant blue, 30%
methanol and 10% acetic acid) and destained in the same solution
without Coomassie brilliant blue and were dried directly between
dialysis membranes.
2.5. Promoter activity assays
E¡ect of PGE2, NS398 and indomethacin on MMP-2 promoter
activity was analyzed as described previously [24]. Cells were plated
onto six-well plates at a density of 105 cells/well and grown overnight.
Cells were cotransfected with 2 Wg of MMP-2 promoter^luciferase
reporter construct (kindly provided by Dr. Benveniste) and 2 Wg of
L-galactosidase reporter plasmid by the LipofecAMINE method. Cells
were cultured in 10% FCS medium and incubated with vehicle or
drugs for 24 h. Luciferase activity and L-galactosidase activity were
assayed by using the luciferase and L-galactosidase enzyme assay sys-
tem (Promega). Luciferase activity was normalized with the L-galac-
tosidase activity in cell lysate and calculated as an average of three
independent experiments.
3. Results
We ¢rst address whether COX-2 inhibitor NS398 may af-
fect the expression and activation of MMP-2 and MMP-9.
Control or drug-treated cells were harvested and the mRNA
level of MMP-2 and MMP-9 was analyzed by RT-PCR. As
shown in Fig. 1, our results indicated that NS398 inhibited
MMP-2 expression in a dose-dependent manner. Conversely,
NS398 could not regulate the expression of MMP-9. The e⁄-
ciency of cDNA synthesis and PCR ampli¢cation was checked
by using a pair of primers designed to amplify G3PDH gene
fragment. A single band with predicated size (283 bp) was
detected in all samples and similar levels of this gene fragment
were observed in all samples. We next investigated the
amounts of MMP-2 secreted into the culture medium by
Western blot analysis. Our data con¢rmed the results of
RT-PCR and showed that NS398 reduced the amounts of
active MMP-2 protein (66 kDa), but not active MMP-9 (83
kDa), in the conditioned medium (Fig. 2). We also investi-
gated the expression and processing of MMP-2 in cells. As
demonstrated in Fig. 3A, synthesis of MMP-2 precursor pro-
tein (72 kDa) and processing of this precursor to the active
form of MMP-2 were dramatically inhibited by NS398. In
addition, NS398 e¡ectively suppressed MMP-2 activity in
the culture medium as demonstrated by zymographic assays
(Fig. 3B).
Because NS938 down-regulated MMP-2 mRNA in lung
cancer cells, we proposed that NS398 might directly a¡ect
MMP-2 expression by inhibiting gene transcription. We ad-
dressed this question by analyzing the e¡ect of NS398 on
MMP-2 promoter activity. Cells were transfected with
MMP-2 promoter^luciferase construct, treated with di¡erent
concentrations of NS398 for 24 h. and luciferase activity was
determined. As shown in Fig. 4, our results demonstrated that
NS398 suppressed MMP-2 promoter activity in a dose-depen-
dent manner. Additionally, we found that a non-selective
COX inhibitor indomethacin also potently inhibited MMP-2
promoter activity. Because PGE2 is the enzymatic product of
COX, we tested whether PGE2 might reverse the inhibitory
e¡ect of NS398 on MMP-2 promoter activity. Our results
demonstrated that suppression of MMP-2 promoter activity
by NS398 was partially reversed by PGE2 in lung cancer cells
(Fig. 5). These data suggest that NSAIDs may directly inter-
fere MMP-2 expression and the inhibitory action of these
drugs may not be totally dependent on their ability to inhibit
COXs.
Fig. 1. NS398 inhibits MMP-2, not MMP-9, expression in lung can-
cer cells. A549 cells were cultured in 10% FCS medium containing
vehicle or di¡erent concentrations of NS398 for 24 h. Total RNA
was isolated and mRNA level of MMP-2, MMP-9 and G3PDH
were examined by RT-PCR analysis. Ampli¢ed cDNA products
were run on 2% agarose gels, stained with ethidium bromide and vi-
sualized under UV light.
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4. Discussion
Lines of evidence have demonstrated that COX inhibitors
exhibit potent anti-angiogenic and anti-metastatic activity in
vitro and in vivo [25,26]. However, the molecular mechanism
of these actions is not clear. Recent studies indicate that
MMPs play important roles in the development of metastasis
and angiogenesis. Because MMP-2 and -9 are the principle
enzymes that involved in the degradation of type IV collagen
in the extracellular matrix, it has been proposed that these two
MMPs are key players in cancer invasion and metastasis. In-
deed, a positive correlation between the expression of MMP-2
and -9 and tumor metastasis has been observed in human lung
cancer [27,28].
Two crucial ¢ndings in our study should be noted. First,
this work is the ¢rst one to demonstrate that COX inhibitors
may directly inhibit MMP-2 expression via repression of gene
transcription. A number of potential regulatory elements in-
cluding Sp1, Ap-1, Ap-2, CREB, C/EBP, Ets-1, c-Myc, and
PEA3 binding sites have been identi¢ed in the human MMP-2
promoter [29]. We are now investigating the signaling path-
way by which these inhibitors inhibit MMP-2 expression and
mapping the critical regions in the MMP-2 promoter that
mediated this inhibitory e¡ect. Second, because the concen-
tration of NS398 needed to suppress the expression of MMP-
Fig. 2. Protein level of MMP-2, but not MMP-9, in the conditioned
medium was reduced by NS398. A549 Cells were cultured in serum-
free medium containing vehicle or 100 WM NS398 for 24 h. Condi-
tioned medium was concentrated 25-fold and equal amounts, based
on cell numbers determined at the time of harvest, of supernatant
were separated by SDS^PAGE. MMP-2 and MMP-9 protein level
were determined by Western blot analysis.
Fig. 3. NS398 inhibits MMP-2 protein synthesis, processing and en-
zymatic activity. A: Cells were treated with vehicle or 100 WM
NS398 for 24 h. Cellular proteins were extracted and synthesis and
processing of MMP-2 was investigated by Western blot analysis. B:
Cells were cultured in serum-free medium containing vehicle or 100
WM NS398 for 24 h. Conditioned medium was concentrated 25-fold
and equal amounts, based on cell numbers determined at the time
of harvest, of supernatant were subjected to zymographic assay as
described in Section 2.
Fig. 4. COX inhibitor NS398 and indomethacin suppress MMP-2
promoter activity in a dose-dependent manner. A549 cells were co-
transfected with 2 Wg of MMP-2 promoter^luciferase construct and
2 Wg of L-galactosidase reporter plasmid by the LipofecAMINE
method. Cells were incubated with vehicle or di¡erent concentra-
tions (20 or 100 WM) of NS398 (NS) or indomethacin (IN) for 24 h.
Luciferase activity was determined, normalized with L-galactosidase
activity and expressed as the percentage of that of vehicle-treated
cells.
Fig. 5. PGE2 partially reverses NS398-induced inhibition of MMP-2
promoter activity. A549 cells were cotransfected with 2 Wg of
MMP-2 promoter^luciferase construct and 2 Wg of L-galactosidase
reporter plasmid and incubated with vehicle (C) or 100 WM NS398
(NS) or 100 WM NS398+10 WM PGE2 (NS+PG) for 24 h. Lucifer-
ase activity was determined, and normalized with L-galactosidase ac-
tivity and expressed as the percentage of that of vehicle-treated
cells.
FEBS 25507 20-11-01
M.-R. Pan et al./FEBS Letters 508 (2001) 365^368 367
2 is much higher than the concentration of NS398 needed to
block the enzymatic activity of COX-2, we speculate that the
e¡ect of NS398 on MMP-2 expression is not totally dependent
on inhibition of COX-2 activity. Indeed, a non-selective COX
inhibitor indomethacin also exerts similar inhibition of MMP-
2 expression. Furthermore, addition of a high dose of PGE2
only partially reversed the action of NS398. Interestingly, a
very recent study demonstrated that aspirin, another non-se-
lective COX inhibitor, may e¡ectively inhibit MMP-2 produc-
tion and migration of hepatoma cells [30]. However, the au-
thors did not elucidate the mechanism of this action. Our data
provide a molecular basis for the anti-angiogenic and anti-
metastatic action of NSAIDs.
Taken together, we test the hypothesis that COX inhibitors
may suppress the activity of MMPs to inhibit tumor angio-
genesis and metastasis in this work. Our results support this
notion and suggest that NSAIDs may be useful for the treat-
ment or prevention of metastasis of lung cancer.
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